Dark chocolates vs dates: Which is the healthier sweet for your pantry?
Sugar ContentDark chocolate is considered a heart-healthy food, and experts agree. Now, the quantity of sugar may vary in different varieties, but when the cocoa percentage is higher, the sugar content is generally lower. Therefore, experts recommend dark chocolate, which is at least 70 to 80 per cent rich.Meanwhile, dates are nature's candy with a high glycaemic index. 'Dates have natural sugar, which is approximately 68.84g in 100g, and may also trigger further sugar cravings due to their relatively high glycaemic load,' Vani Krishna, chief nutritionist at Manipal Hospital, Varthur tells India Today.
Dark chocolate is rich in antioxidants (Photo: Pexels)
Antioxidant-richDark chocolate is not just a treat but an antioxidant powerhouse. It has high flavonoid (plant-based antioxidant) content, especially when it contains over 75 per cent cocoa. This results in several heart health benefits, such as improved vascular function, lower blood pressure, and enhanced insulin sensitivity. These effects are attributed to the presence of compounds like epicatechin and catechin, which have been shown to reduce oxidative stress and inflammation, the nutritionist explains.In contrast, dates are rich in potassium, magnesium, and vitamin B6 but their cardiovascular benefits are less pronounced due to their high natural sugar content.Fibre and feeling of fullnessDates are a rich source of dietary fibre, with about 3.3 grams per two medium-sized dates, making them excellent for promoting digestion and satiety.Dark chocolate, too, can help keep your appetite in check. How? It contains polyphenols that stimulate the release of satiety hormones such as GLP-1 and PYY, which aid in appetite control and reduce cravings. This makes it a viable option for those looking to maintain a balanced diet without overindulging in sugar.
Dates are rich in fibre and minerals (Photo: Pexels)
MineralsNow this is one area where both these foods add value of their own. Dates are packed with potassium, magnesium, iron, and fibre, supporting bowel movements and gut health. However, for those monitoring sugar intake, dark chocolate is a preferable option, containing substantially less sugar than dates, especially if consumed in its unsweetened form.Although dark chocolate also provides significant amounts of iron, magnesium, and copper, it stands out for its antioxidant-rich profile—which, according to nutritionist Vani Krishna, surpasses that of dates. These antioxidants not only help reduce inflammation but also support overall cardiovascular health.And let's not forget the emotional side - chocolate and feelings share a deep connection. A bite of dark chocolate can lift your mood, but that doesn't mean you should overindulge.Final biteOverall, the choice between dark chocolate and dates depends on individual dietary needs and health goals. Dark chocolate appears to have an edge in terms of heart health and antioxidant properties, making it a valuable addition to a balanced diet when consumed in moderation. 'I would suggest dark chocolate is healthy as it contains the richest dietary sources of flavanols, including epicatechin and catechin. It is proven to reduce oxidative stress, improve vascular function, and help to lower inflammatory markers,' says Krishna.advertisementMeanwhile, dates, with their high fibre and mineral content, are an excellent choice for digestive health but should be eaten with caution due to their high glycaemic index.While moderation is key when it comes to food, one thing is certain – both options can be healthier alternatives to processed sugary snacks if integrated thoughtfully into one's diet.- EndsTrending Reel
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
8 hours ago
- The Hindu
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug
Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused on HIV medicines and majority owned by GSK with Pfizer and Shionogi as shareholders, and Medicines Patent Pool (MPP) extending their voluntary licensing agreement to enable access to long-acting injectable HIV treatment. It builds on the voluntary license for CAB LA for HIV pre-exposure prophylaxis (PrEP). The announcement, on extending their agreement, comes in the wake of an updated guidance from World Health Organization (WHO) recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option. Existing licensees Aurobindo, Cipla and Viatris will consequently be able to develop, manufacture and supply generic versions of CAB LA, for use in combination with long-acting rilpivirine, for the treatment of HIV-1 infection in adults and adolescents weighing at least 35kg subject to required regulatory approvals being obtained, Aurobindo Pharma said on Tuesday. Vice chairman and MD of Aurobindo Pharma K. Nithyananda Reddy said the company remains committed to leveraging its global supply capabilities to make the vital combination long-acting injection therapy widely available and affordable. The consideration by ViiV and MPP to include the private market in royalty-bearing countries is a critical step toward expanding access across both public and private sectors, he said.
Hindustan Times
9 hours ago
- Hindustan Times
Producer-actor Dheeraj Kumar dies at 80 of acute pneumonia: Causes, early signs, prevention
Veteran actor and producer Dheeraj Kumar, passed away earlier today, days after being admitted to Mumbai's Kokilaben Dhirubhai Ambani Hospital, owing to acute respiratory distress. As per an India Today report, Dheeraj had been shifted to the Intensive Care Unit of the hospital and put on a ventilator, efforts which ultimately proved futile in saving him. Dheeraj Kumar, 80, dies of acute pneumonia: Early signs to watch for(Photo: iStock) Known for his work across Punjabi films, Hindi films as well as television, one of his last public appearances was at the inauguration of the ISKCON temple in Kharghar, Navi Mumbai. Dheeraj, 80 at the time of his passing, is survived by wife Zuby Kochar. The actor's demise came as a result of complications stemming from acute pneumonia, which in some cases, can prove to be fatal. A report by Mayo Clinic however, lists out the symptoms as well as when to alert a doctor so as to receive swift treatment. What is pneumonia? Pneumonia is an infection that causes inflammation in the air sacs of one or both lungs. These sacs can become filled with fluid or pus, leading to symptoms such as coughing with mucus or pus, fever, chills, and trouble breathing. Anything from bacteria, viruses, and fungi can trigger this diagnosis. While pneumonia can very well be caught at an early, mild stage, if left unattended or unmedicated for too long, can very likely prove to be fatal. Adults over the age of 65 and infants and young children, particularly those with comparatively weaker immune systems and other pre-existing health conditions, are more susceptible to the illness. A Healthline report lists the types of pneumonia as hospital-acquired pneumonia, community-acquired pneumonia, ventilator-associated pneumonia and aspiration pneumonia. While the first three are self explanatory, the last, aspiration pneumonia, is the result of inhaling bacteria into the lungs via food, drink, or saliva. What are the signs and symptoms of pneumonia? The Healthline report lays out a comprehensive list of symptoms to keep an eye out for. Chest pain when you breathe or cough, confusion or changes in mental awareness (in adults age 65 and older), phlegm producing cough, fatigue, fever, sweating and shaking chills, lower than normal body temperature (particularly in adults), nausea, vomiting or diarrhea and shortness of breath. When to see a doctor? The Mayo Clinic report asserts that difficulty breathing, chest pain, a persistent fever of 102F or higher or a persistent cough, especially with pus, is more than enough reason to go visit a doctor. This specifically applies to those with already weaker immune systems (naturally or because of certain medication) or even exposure like chemotherapy. Coming back to Dheeraj, may he rest in peace.
Time of India
10 hours ago
- Time of India
India's Obesity Crisis Meets ‘Miracle Drugs' — Are We 'Flying Blind' Into Another Health Disaster?
New Delhi: As India grapples with a staggering 254 million people living with overweight or obesity, the arrival of weight-loss drugs or weight-related drugs has ignited both hope—and alarm. At an exclusive Healthworld webinar, top Indian clinicians warned: this could be a transformative moment in chronic disease care , or it could spiral into unregulated chaos. The experts had one message in unison: GLP-1s are not to be used as cosmetics. They are clinical tools. And misuse could unleash a crisis. The webinar titled 'Weighing In: India's Medical Weight-loss Revolution,' the session brought together leading cardiologists, endocrinologists, and surgeons to examine to know if the new class of drugs are helping into major shift India's obesity or getting on to be a pandora's box. The leading doctors participating in the panel were Dr. Ashok Seth, Chairman, Fortis Escorts Heart Institute, Dr. Shashank Joshi, Consultant, Department of Diabetology and Endocrinology, Lilavati Hospital & Research Centre and Dr. Muffazal Lakdawala, Director, General Surgery & Minimal Access Surgical Sciences, Edge & Reliance Foundation Hospital. A few of the drugs in India that are used for weight-loss include Orlistat, Liraglutide (Victoza), Semaglutide (Wegovy and Rybelsus) and tirzepatide (Mounjaro). Among these, Orlistat is one of the early drugs that was specifically approved for obesity treatment, while the others are among the newly approved for weight loss treatment. Just as the hype grows, a Public Interest Litigation (PIL) has reached the Delhi High Court, warning against the aggressive marketing and uncontrolled sale of GLP-1 drugs in gyms and wellness clinics. As the drugs grow in popularity, they are increasingly being peddled without prescriptions, fuelling fears of another health disaster. 'These are prescription-only drugs,' warned Dr Shashank Joshi, leading endocrinologist from Lilavati Hospital. 'They are meant for high-risk patients with obesity and metabolic diseases—not for healthy people chasing cosmetic goals. Dispensing them without supervision is not just illegal—it's dangerous.' A New Era in Obesity Treatment—If Done Right Unlike the banned appetite suppressants of the past, GLP-1 receptor agonists come with robust evidence from global trials. The SELECT trial showed a 20 per cent reduction in major cardiovascular events in patients treated with semaglutide. 'Obesity is no longer about appearance. It's a chronic, systemic disease,' said Dr. Ashok Seth, Chairman, Fortis Escorts Heart Institute. 'For the first time, we have a pharmacological tool that reduces not just weight, but real, hard endpoints like heart attacks and strokes. That changes everything.' Dr. Muffazal Lakdawala, renowned bariatric surgeon, was blunt: 'India is sitting on a ticking obesity bomb. And if we let these drugs turn into gym-floor fads, we will be repeating the antibiotic misuse crisis.' He added, 'These are not shortcuts to six-packs. They are meant for carefully selected patients. I reject 90 per cent of surgical weight-loss requests for being inappropriate—now imagine how many unqualified people are chasing these drugs for the wrong reasons.' One of the most powerful takeaways from the panel was the push to reframe obesity not as a failure of will power but as a chronic, relapsing medical condition—with roots in genetics, environment, and biology. 'We must stop fat-shaming,' said Dr. Joshi. 'And we must stop using outdated tools like BMI alone. Indian bodies are metabolically different—what we call 'thin-fat'—lean on the outside but high in visceral fat and risk inside.' Experts informed that lifestyle change remains essential, but for many, especially those with BMI over 27 with comorbidities, GLP-1 drugs may be the difference between disease progression and reversal. The panel stressed that with power comes responsibility. India lacks a real-time pharmacovigilance system to monitor off-label use or adverse effects—unlike in the US or Europe. 'We are flying blind,' said Dr. Joshi. 'Without safeguards, this miracle will become a mess. Regulators must enforce prescription protocols and clamp down on black-market supply before it's too late.' Talking about the affordability vs access of these weight-loss drugs the experts informed that with semaglutide injections priced at ₹26,000/month, affordability remains a major hurdle. But doctors argued that the cost of untreated obesity—dialysis, bypass surgeries, stroke rehab—is far higher. Dr Lakdawala put it simply: 'We must think in terms of cost-effectiveness, not sticker price. And as generics enter the market, access can improve—but only if regulation keeps pace.' This Is Science, Not Vanity Across the board, experts made an urgent appeal to ditch the 'weight-loss drug' label. 'These are disease-modifying agents that can prevent diabetes, reverse fatty liver, and cut heart disease,' said Dr. Seth. 'Calling them cosmetic trivializes their life-saving potential.' Dr. Joshi added, 'Let's not rob the sick to serve the slim. Off-label demand abroad has already caused shortages. India must prioritize medical need, not market hype.' India stands at a crucial crossroads. With GLP-1 drugs offering a powerful tool to manage obesity, diabetes, and heart disease, the path forward must be one of caution, regulation, education, and equity, added experts. Summing it up well, Dr Joshi said, "We are in the best of times for chronic disease innovation. But we're also in the worst of times—if we let hype override science.'
